177Lu-PSMA-617 (PluvictoTM), which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, was the first FDA-approved PSMA-targeting therapy for metastatic PCa patients in 2022. Here, FOLH1 is linked to posterior cortical atrophy.